---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087859"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:20:24.385179+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cellectar restates 2022-2024 financials; warrant accounting error triggers non-reliance

## Summary
- Board concludes FY2022, FY2023 audited and Q1-Q3 2023, Q1 2024 interim statements are unreliable.
- Errors stem from accounting treatment of warrants issued in October 2022 financing.
- Restatement required; company unable to estimate amount or effect at this time.
- Filing of Q2 2024 Form 10-Q will be delayed pending restatement.
- Discussed with current auditor Deloitte and former auditor Baker Tilly.

## SEC filing metadata
- accession: 0001104659-24-087859
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924087859/0001104659-24-087859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924087859/tm2421322d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087859
- JSON: https://secwatch.observer/filing/0001104659-24-087859.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.